7
Participants
Start Date
February 19, 2020
Primary Completion Date
November 11, 2024
Study Completion Date
December 2, 2024
IOV-2001
Adoptive cell therapy (ACT) manufactured from peripheral blood lymphocytes (PBL). The final investigational product is a cryopreserved cell suspension.
Low dose IL-2
6 doses of subcutaneous (SC) LD-IL-2 (9 MIU every 8-12 hours) will follow the infusion of IOV-2001
High dose IL-2
6 doses of IV HD-IL-2 (600,000 IU/kg Q8-12H will follow the infusion of IOV-2001
IL-2
6 doses of IL-2 will follow the infusion of IOV-2001
Allegheny Health, Pittsburgh
Duke University, Durham
Moffitt Cancer Center, Tampa
Baptist Cancer Center, Memphis
Ohio State University, Columbus
University of Cincinnati Medical Center, Cincinnati
University of Utah, Huntsman Cancer Institute, Salt Lake City
Lead Sponsor
Iovance Biotherapeutics, Inc.
INDUSTRY